Table 1 Baseline patient characteristics
Patients, n | 98 |
Sex, n (%) | Male, 63 (64.3); Female, 35 (35.7) |
Age, median (range) | 73 (44-89) |
Metastasis, n (%) | |
Adrenal | 19 (19.4) |
Bone | 26 (26.5) |
Brain | 10 (10.2) |
Lymph nodes | 37 (37.8) |
Lung | 45 (45.9) |
Weight, mean (SD) | 70.06 (13.37) |
PD-L1 TPS percentage, n (%) | |
Less than 75% | 46 (46.9%) |
Greater or equal to 75% | 52 (53.1%) |
ECOG-PS at first cycle (%) | |
0 | 25 (25.5) |
1 | 64 (65.3) |
2 | 9 (9.2) |
Follow-up, median in months | 13 |
Duration of treatment, median in cycles | 8.5 |
Overall toxicity (%) | 76 (77.5) |
Cutaneous toxicity (%) | 29 (30.1) |
Gastrointestinal toxicity (%) | 27 (27.5) |
Endocrinological toxicity (%) | 20 (20.4) |
Other toxicity (%) | 67 (68.4) |